This week, the protein industry is looking beyond what can be developed in the lab to what it takes to make those ideas work at scale. Manufacturing platforms are being brought together, R&D infrastructure is becoming more accessible, and investment is helping technologies move closer to commercial reality.
That shift is especially clear in cultivated protein. A new acquisition brings aquatic cell platforms, animal-component-free media expertise, and manufacturing capabilities under one roof, with cultivated protein ingredients for premium pet food among the early applications. It reflects a sector becoming more integrated as developers seek clearer routes from cell biology to production.
The same push is visible across the broader ecosystem. A new food innovation hub is combining bioprocessing, prototyping, formulation, testing, and scale-up, while new ingredient capacity in Mexico and a modular bioreactor model aim to make production more flexible. For smaller developers, access to the right equipment may be just as important as access to capital.
That focus on flexibility is also shaping biomanufacturing itself. A modular bioreactor model is targeting one of the sector’s persistent bottlenecks: scaling production without requiring large, capital-intensive facilities from the outset. The approach could offer developers a more adaptable route as they move from pilot projects toward commercial production.
At the ingredient level, a sunflower-based fat system is entering its next commercial phase, while more than £1 million is supporting 33 UK alternative protein projects across academia and industry. Progress, in other words, is happening across the supply chain, from formulation and R&D to manufacturing and scale-up.
The bigger story is how these pieces are connecting. The industry’s next stage may depend less on breakthroughs and more on the infrastructure, partnerships, and production models needed to build viable businesses.
